Publications found:
36,694
Sort by:
Cempra: “GAIN from Drugs for Bad Bugs”
US$ 140.00
Drug resistance is a growing concern worldwide and Cempra (CEMP) is one of our lead recommendations ... offer an attractive investment opportunity in this therapy class. CEMP’s lead drug, 1. Solithromycin (CEM-101, PhIII, CABP; PhII cUTI) ... released on 2nd July, 2012 on CEMP titled “GAIN from Drugs for Bad Bugs”
July 2012
9 pages
Competitor Analysis: Dengue Virus Vaccines and Therapeutics
US$ 243.00
... of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...
July 2012
27 pages
China Genetic Engineering Drug Industry Report, 2011-2012
US$ 1,900.00
China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs...
July 2012
80 pages
Medical Laboratories: Market Research Report
US$ 4,800.00
... report analyzes the worldwide markets for Medical Laboratories in US$ Million by the following Product Segments: Hospital-Based Medical Laboratories, and Others. The ... through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 162 companies including many key and ...
July 2012
682 pages
Needle-Free Drug Injection Systems and Safety Syringes: Market Research Report
US$ 4,600.00
This report analyzes the worldwide markets for Needle-Free Drug Injection Systems and Safety Syringes in US$ Million. The report provides ... , Inc., Cambridge Consultants Ltd., Antares Pharma, Inc., Bard Biopsy Systems, Baxter International, Inc., Baxter BioPharma Solutions, Bector, Dickinson, BD Medical, ...
July 2012
504 pages
Pharma sales force shape, size and structure — where next?
US$ 595.00
... — Pharma sales force shape, size and structure — where next? — analyses the key issues influencing sales force objectives and structure; how some pharma companies have restructured their sales and marketing channels, and whether these changes have been successful or not. Report Overview Pharma sales force shape, size ...
July 2012
68 pages
Onyx Pharma – Kyprolis to Accelerate Growth
US$ 140.00
... events – cardiovascular toxicities and deaths associated with Kyprolis as expected. ONXX has finally succeeded in ... Nexavar (L, RCC, HCC, partnered with Bayer), Kyprolis, and Regorafenib (R, oral multi-kinase inhibitor, GIST ... on Jun 21, 2012 on Onyx Pharma titled “Onyx Pharma - Kyprolis to Accelerate Growth”
June 2012
4 pages
Prioritizing Generic Drug development pipeline – The top Fifty Opportunities
US$ 5,000.00
... crucial aspects of growth strategy for a generic company or an Active Pharmaceutical Ingredient manufacturing ... recently approved or are in late stage development / Filed but with significantly success probability ... / therapeutic value compared to marketed drugs Anticipated competition in the therapy and ...
June 2012
100 pages
OTC Drug Market in India 2012
US$ 950.00
... days after order is placed. Over-the-counter drug market in India ranks eleventh in the global OTC market and is expected to reach the ninth position ... tendency for self treatment, the Indian market is characterized by a huge demand for OTC drugs. It is a highly fragmented market with a large number of foreign ...
June 2012
85 pages
Production Situation of Vitamin E in China
US$ 1,620.00
In volume of transaction, Vitamin E is one of the world's top three vitamins with annual global market volume of nearly USD1 billion, thanks to the wide range of applications in feed, medicine and foo...
June 2012
20 pages
Competitor Analysis: RSV Vaccines and Therapeutics
US$ 315.00
Competitor Analysis: Respiratory Syncytial Virus (RSV) Vaccines and Therapeutics The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a ... RSV disease in infants and children at high risk for severe lung disease from RSV, a RSV vaccine still is not on the market. A number ...
June 2012
30 pages
Asia Pacific Pharma Sector Analysis
US$ 1,300.00
The Asia-Pacific region is emerging as the fastest growing pharmaceutical industry in the global pharmaceutical arena. In the recent years, the demand for healthcare services has risen among the regio...
June 2012
160 pages
Effective Sales and Marketing Strategies for Orphan Drugs
US$ 695.00
The real potential for orphan drug pharma marketing With drug pipelines moving from essential products to niche therapies, large pharma companies are increasingly attracted to the prospective high de...
June 2012
117 pages
Insulin Market Forecast to 2015
US$ 400.00
In the global biopharmaceutical industry, protein-based therapies are effectively being used to treat metabolic disorders, and autoimmune diseases. According to our new research report, the global mar...
June 2012
42 pages
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics
US$ 394.00
The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules as well as DNA-, RNA- and microorganism-based therapies against infection with ...
May 2012
46 pages
Kidney Cancer Drugs: Market Research Report
US$ 4,500.00
... report analyzes the worldwide markets for Kidney Cancer Drugs in US$ Million. This report on 'Kidney Cancer Drugs' provides market analytics specifically for ... Ltd., GlaxoSmithKline Plc, Merck-Serono, Novartis AG, Pfizer, Inc., and WILEX AG. Market data and analytics are derived from primary and secondary ...
May 2012
297 pages
Cardiovascular Pharmaceuticals Market in India 2012
US$ 950.00
... days after order is placed. Cardiovascular pharmaceuticals market in India is the second largest contributor to domestic pharmaceutical sales, contributing around 15.6%. Since India has a huge patient pool, the ...
April 2012
71 pages
2012 Global Drugs of Abuse Testing Market Outlook: Growth Opportunities and Strategies
US$ 6,000.00
... a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. "Drugs of Abuse Testing Market: US, Europe, Japan" is a unique study designed to help current suppliers and potential market entrants identify and evaluate emerging ...
April 2012
311 pages
China's Pharmaceutical Industry 2011
US$ 600.00
This report describes the general development of China’s pharmaceutical industry in aspects of investment, production, sales, import & export, major prices and operations.
April 2012
15 pages
Clinical Trials Market in India 2012
US$ 950.00
... into the market and highlights the market size and growth of clinical trials in the country. India’s current and projected share in the global clinical trials market has also ...
April 2012
58 pages
Global Drugs Retail Industry 2012 - 2017: Trend, Profit, and Forecast Analysis
US$ 1,980.00
... the Global Drug Retail market and presents its findings in “Global Retail Drug Industry 2012-2017: Trend, Profit, and Forecast Analysis.” The drug industry consists of pharmacies and drug ... (Q1 2012 – Q4 2012) for global drugs retail industry analysis Gross and net profit trends in the global drugs retail industry analysis Cost structure trend in the global as well as regional global drugs retail industry ...
April 2012
-
RNA Interference (RNAi): Market Research Report
US$ 4,800.00
This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following Application Areas: Drug Discovery and Target ... , Inc., Exiqon A/S, Genesis Research & Development Corporation Limited, Halo-Bio RNAi Therapeutics, Inc., Marina Biotech, Inc., OPKO Health, Inc., Polyplus- ...
April 2012
792 pages
Research Report on Chinese Bio-pharmaceutical Industry, 2012
US$ 3,000.00
In China, biological products consist of vaccines, blood products, cytokine, diagnostic reagents and other active agents (including toxins, antigens, allergen, and recombinant DNA products, etc.). In...
March 2012
60 pages
Compulsory License: India Pharma’s solution to “Patent and Affordability”
US$ 140.00
Recently, Natco was granted the first Compulsory License in India for the anti-cancer drug ‘Nexavar’. In an early test of India’s requirement that patent monopolies will ... now give rise to opportunities for other large cap global pharma companies too, as they can also seek a CL for other best ...
March 2012
8 pages
Research Report on Chinese Human Vaccine Industry, 2012
US$ 3,000.00
The research object of the report is human vaccine apart from animal vaccine. Vaccination is the most economical, effective, safe and convenient way to prevent disease and the investment of vaccinatio...
March 2012
50 pages
Onyx Pharma - Banking on Carfilzomib’s Approval or Acquisition!
US$ 90.00
... Bayer for Japan royalties made FY11 a profitable year for Onyx pharma (ONXX), we do not expect it to be sustainable as high operating expenses (h43% YoY ... detail, please read our report released on 2nd Mar., 2012 on Onyx Pharma titled “Onyx Pharma - Banking on Carfilzomib’s Approval or Acquisition!”
March 2012
4 pages
Analyzing the Indian Pharmaceutical Industry
US$ 300.00
... which have already been committed to the Government of India. The Indian pharmaceutical industry has a unique amalgamation of three critical factors ... global drug producing nations. Aruvian's R'search’s report on Analyzing the Indian Pharmaceutical Industry is an extensive outlook on the industry which explains ...
March 2012
75 pages
Indian Pharmaceutical Industry – SWOT Framework Analysis
US$ 175.00
The Indian pharmaceutical industry is one of the fast growing sectors of the Indian economy and has made ... and become significant players in the international market. SWOT Analysis, is a strategic planning tool used to ... achieving that objective. The aim of any SWOT analysis is to identify the key internal and ...
March 2012
20 pages
Pharmaceutical Industry in India – PEST Framework Analysis
US$ 175.00
... like US and Europe. In the recent past, several pharmaceutical companies have demonstrated that they possess the ability to engage ... significant players in the international market. Aruvian's R'search analyzes the Pharmaceutical Industry in India in a PEST Framework Analysis. A PEST analysis is concerned with ...
March 2012
20 pages
